Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Aggressive Variant Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Metastatic Prostate Neuroendocrine Carcinoma
Metastatic Prostate Small Cell Carcinoma
Stage IV Prostate Cancer AJCC v8

Interventions

DRUG: Cabazitaxel
DRUG: Carboplatin
BIOLOGICAL: Cetrelimab
DRUG: Niraparib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]